Counter-regulation of alpha- and beta-synuclein expression at the transcriptional level

Molecular and Cellular Neuroscience

Volumn 57, Issue , 2013, Pages 33-41

  Wright, Josephine A ^a   McHugh, Patrick C ^a   Pan, Siyi ^a   Cunningham, Adam ^a   Brown, David R ^a  

^a University of Bath   (United Kingdom)

Author keywords

NRF2; Parkinson's disease; Synuclein; Transcription factors; ZSCAN

Indexed keywords

ALPHA SYNUCLEIN; BETA SYNUCLEIN; SYNUCLEIN; TRANSCRIPTION FACTOR; TRANSCRIPTION FACTOR ZSCAN; TRANSCRIPTION FACTOR ZSCAN21; UNCLASSIFIED DRUG;

ARTICLE; CELL AGGREGATION; CELL GROWTH; CONTROLLED STUDY; GENE REPRESSION; HUMAN; HUMAN CELL; NERVE CELL; NEUROBLASTOMA CELL; PRIORITY JOURNAL; PROTEIN AGGREGATION; PROTEIN ANALYSIS; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN LOCALIZATION; SIGNAL TRANSDUCTION; TRANSCRIPTION REGULATION;

NRF2; PARKINSON'S DISEASE; SYNUCLEIN; TRANSCRIPTION FACTORS; ZSCAN;

ALPHA-SYNUCLEIN; BETA-SYNUCLEIN; CELL LINE, TUMOR; HUMANS; RNA, MESSENGER; TRANSCRIPTION FACTORS; TRANSCRIPTIONAL ACTIVATION;

EID: 84885402281     PISSN: 10447431     EISSN: 10959327     Source Type: Journal    
DOI: 10.1016/j.mcn.2013.09.002     Document Type: Article

References (55)

1. Adams M.D., Kelley J.M., Gocayne J.D., Dubnick M., Polymeropoulos M.H., Xiao H., Merril C.R., Wu A., Olde B., Moreno R.F., et al. Complementary DNA sequencing: expressed sequence tags and human genome project. Science 1991, 252:1651-1656.
2. Barone M.C., Sykiotis G.P., Bohmann D. Genetic activation of Nrf2 signaling is sufficient to ameliorate neurodegenerative phenotypes in a Drosophila model of Parkinson's disease. Dis. Model. Mech. 2011, 4:701-707.
3. Beyer K., Domingo-Sabat M., Santos C., Tolosa E., Ferrer I., Ariza A. The decrease of beta-synuclein in cortical brain areas defines a molecular subgroup of dementia with Lewy bodies. Brain 2010, 133:3724-3733.
4. Beyer K., Munoz-Marmol A.M., Sanz C., Marginet-Flinch R., Ferrer I., Ariza A. New brain-specific beta-synuclein isoforms show expression ratio changes in Lewy body diseases. Neurogenetics 2012, 13:61-72.
5. Biere A.L., Wood S.J., Wypych J., Steavenson S., Jiang Y., Anafi D., Jacobsen F.W., Jarosinski M.A., Wu G.M., Louis J.C., Martin F., Narhi L.O., Citron M. Parkinson's disease-associated alpha-synuclein is more fibrillogenic than beta- and gamma-synuclein and cannot cross-seed its homologs. J. Biol. Chem. 2000, 275:34574-34579.
6. Burke R.E. Recent advances in research on Parkinson disease: synuclein and parkin. Neurologist 2004, 10:75-81.
7. Carneiro F.R., Silva T.C., Alves A.C., Haline-Vaz T., Gozzo F.C., Zanchin N.I. Spectroscopic characterization of the tumor antigen NY-REN-21 and identification of heterodimer formation with SCAND1. Biochem. Biophys. Res. Commun. 2006, 343:260-268.
8. Chiba-Falek O., Nussbaum R.L. Effect of allelic variation at the NACP-Rep1 repeat upstream of the alpha-synuclein gene (SNCA) on transcription in a cell culture luciferase reporter system. Hum. Mol. Genet. 2001, 10:3101-3109.
9. Chiba-Falek O., Kowalak J.A., Smulson M.E., Nussbaum R.L. Regulation of alpha-synuclein expression by poly (ADP ribose) polymerase-1 (PARP-1) binding to the NACP-Rep1 polymorphic site upstream of the SNCA gene. Am. J. Hum. Genet. 2005, 76:478-492.
10. Chiba-Falek O., Lopez G.J., Nussbaum R.L. Levels of alpha-synuclein mRNA in sporadic Parkinson disease patients. Mov. Disord. 2006, 21:1703-1708.
11. Chowdhury K., Goulding M., Walther C., Imai K., Fickenscher H. The ubiquitous transactivator Zfp-38 is upregulated during spermatogenesis with differential transcription. Mech. Dev. 1992, 39:129-142.
12. Clough R.L., Dermentzaki G., Stefanis L. Functional dissection of the alpha-synuclein promoter: transcriptional regulation by ZSCAN21 and ZNF219. J. Neurochem. 2009, 110:1479-1490.
13. Clough R.L., Dermentzaki G., Haritou M., Petsakou A., Stefanis L. Regulation of alpha-synuclein expression in cultured cortical neurons. J. Neurochem. 2011, 117:275-285.
14. Davies P., Wang X., Sarell C.J., Drewett A., Marken F., Viles J.H., Brown D.R. The synucleins are a family of redox-active copper binding proteins. Biochemistry 2010, 50:37-47.
15. Davies P., Moualla D., Brown D.R. Alpha-synuclein is a cellular ferrireductase. PLoS One 2011, 6:e15814.
16. Ellerton E.L., Thompson W.J., Rimer M. Induction of zinc-finger proliferation 1 expression in non-myelinating Schwann cells after denervation. Neuroscience 2008, 153:975-985.
17. Fan G.H., Zhou H.Y., Yang H., Chen S.D. Heat shock proteins reduce alpha-synuclein aggregation induced by MPP+ in SK-N-SH cells. FEBS Lett. 2006, 580:3091-3098.
18. Follett J., Darlow B., Wong M.B., Goodwin J., Pountney D.L. Potassium depolarization and raised calcium induces alpha-synuclein aggregates. Neurotox. Res. 2012, 23:378-392.
19. Galvin J.E., Uryu K., Lee V.M., Trojanowski J.Q. Axon pathology in Parkinson's disease and Lewy body dementia hippocampus contains alpha-, beta-, and gamma-synuclein. Proc. Natl. Acad. Sci. U. S. A. 1999, 96:13450-13455.
20. Gan L., Vargas M.R., Johnson D.A., Johnson J.A. Astrocyte-specific overexpression of Nrf2 delays motor pathology and synuclein aggregation throughout the CNS in the alpha-synuclein mutant (A53T) mouse model. J. Neurosci. 2012, 32:17775-17787.
21. Goedert M. Alpha-synuclein and neurodegenerative diseases. Nat. Rev. Neurosci. 2001, 2:492-501.
22. Goers J., Manning-Bog A.B., McCormack A.L., Millett I.S., Doniach S., Di Monte D.A., Uversky V.N., Fink A.L. Nuclear localization of alpha-synuclein and its interaction with histones. Biochemistry 2003, 42:8465-8471.
23. Hashimoto M., Rockenstein E., Mante M., Mallory M., Masliah E. Beta-synuclein inhibits alpha-synuclein aggregation: a possible role as an anti-Parkinsonian factor. Neuron 2001, 32:213-223.
24. Jakes R., Spillantini M.G., Goedert M. Identification of two distinct synucleins from human brain. FEBS Lett. 1994, 345:27-32.
25. Kelner G.S., Lee M., Clark M.E., Maciejewski D., McGrath D., Rabizadeh S., Lyons T., Bredesen D., Jenner P., Maki R.A. The copper transport protein Atox1 promotes neuronal survival. J. Biol. Chem. 2000, 275:580-584.
26. Kruger R., Kuhn W., Muller T., Woitalla D., Graeber M., Kosel S., Przuntek H., Epplen J.T., Schols L., Riess O. Ala30Pro mutation in the gene encoding alpha-synuclein in Parkinson's disease. Nat. Genet. 1998, 18:106-108.
27. Kruger R., Vieira-Saecker A.M., Kuhn W., Berg D., Muller T., Kuhnl N., Fuchs G.A., Storch A., Hungs M., Woitalla D., Przuntek H., Epplen J.T., Schols L., Riess O. Increased susceptibility to sporadic Parkinson's disease by a certain combined alpha-synuclein/apolipoprotein E genotype. Ann. Neurol. 1999, 45:611-617.
28. Lavedan C., Leroy E., Torres R., Dehejia A., Dutra A., Buchholtz S., Nussbaum R.L., Polymeropoulos M.H. Genomic organization and expression of the human beta-synuclein gene (SNCB). Genomics 1998, 54:173-175.
29. Li W., Lesuisse C., Xu Y., Troncoso J.C., Price D.L., Lee M.K. Stabilization of alpha-synuclein protein with aging and familial Parkinson's disease-linked A53T mutation. J. Neurosci. 2004, 24:7400-7409.
30. McHugh P.C., Wright J.A., Brown D.R. Transcriptional regulation of the beta-synuclein 5'-promoter metal response element by metal transcription factor-1. PLoS One 2011, 6:e17354.
31. McLean J.R., Hallett P.J., Cooper O., Stanley M., Isacson O. Transcript expression levels of full-length alpha-synuclein and its three alternatively spliced variants in Parkinson's disease brain regions and in a transgenic mouse model of alpha-synuclein overexpression. Mol. Cell. Neurosci. 2012, 49:230-239.
32. Mikkilineni S., Cantuti-Castelvetri I., Cahill C.M., Balliedier A., Greig N.H., Rogers J.T. The anticholinesterase phenserine and its enantiomer posiphen as 5' untranslated-region-directed translation blockers of the Parkinson's alpha synuclein expression. Park. Dis. 2012, 2012:142372.
33. Mori F., Nishie M., Yoshimoto M., Takahashi H., Wakabayashi K. Reciprocal accumulation of beta-synuclein in alpha-synuclein lesions in multiple system atrophy. Neuroreport 2003, 14:1783-1786.
34. Nam K., Honer C., Schumacher C. Structural components of SCAN-domain dimerizations. Proteins 2004, 56:685-692.
35. Neystat M., Lynch T., Przedborski S., Kholodilov N., Rzhetskaya M., Burke R.E. Alpha-synuclein expression in substantia nigra and cortex in Parkinson's disease. Mov. Disord. 1999, 14:417-422.
36. Ohtake H., Limprasert P., Fan Y., Onodera O., Kakita A., Takahashi H., Bonner L.T., Tsuang D.W., Murray I.V., Lee V.M., Trojanowski J.Q., Ishikawa A., Idezuka J., Murata M., Toda T., Bird T.D., Leverenz J.B., Tsuji S., La Spada A.R. Beta-synuclein gene alterations in dementia with Lewy bodies. Neurology 2004, 63:805-811.
37. Paik S.R., Shin H.J., Lee J.H., Chang C.S., Kim J. Copper(II)-induced self-oligomerization of alpha-synuclein. Biochem. J. 1999, 340(Pt 3):821-828.
38. Park J.Y., Lansbury P.T. Beta-synuclein inhibits formation of alpha-synuclein protofibrils: a possible therapeutic strategy against Parkinson's disease. Biochemistry 2003, 42:3696-3700.
39. Proukakis C., Dudzik C.G., Brier T., Mackay D.S., Cooper J.M., Millhauser G.L., Houlden H., Schapira A.H. A novel alpha-synuclein missense mutation in Parkinson disease. Neurology 2013, 80:1062-1064.
40. Rasia R.M., Bertoncini C.W., Marsh D., Hoyer W., Cherny D., Zweckstetter M., Griesinger C., Jovin T.M., Fernandez C.O. Structural characterization of copper(II) binding to alpha-synuclein: insights into the bioinorganic chemistry of Parkinson's disease. Proc. Natl. Acad. Sci. U. S. A. 2005, 102:4294-4299.
41. Rockenstein E., Hansen L.A., Mallory M., Trojanowski J.Q., Galasko D., Masliah E. Altered expression of the synuclein family mRNA in Lewy body and Alzheimer's disease. Brain Res. 2001, 914:48-56.
42. Rogers J.T., Mikkilineni S., Cantuti-Castelvetri I., Smith D.H., Huang X., Bandyopadhyay S., Cahill C.M., Maccecchini M.L., Lahiri D.K., Greig N.H. The alpha-synuclein 5'untranslated region targeted translation blockers: anti-alpha synuclein efficacy of cardiac glycosides and posiphen. J. Neural Transm. 2011, 118:493-507.
43. Shen Q., Wang Y., Dimos J.T., Fasano C.A., Phoenix T.N., Lemischka I.R., Ivanova N.B., Stifani S., Morrisey E.E., Temple S. The timing of cortical neurogenesis is encoded within lineages of individual progenitor cells. Nat. Neurosci. 2006, 9:743-751.
44. Siddiqui A., Chinta S.J., Mallajosyula J.K., Rajagopolan S., Hanson I., Rane A., Melov S., Andersen J.K. Selective binding of nuclear alpha-synuclein to the PGC1alpha promoter under conditions of oxidative stress may contribute to losses in mitochondrial function: implications for Parkinson's disease. Free Radic. Biol. Med. 2012, 53:993-1003.
45. Sykiotis G.P., Bohmann D. Stress-activated cap'n'collar transcription factors in aging and human disease. Sci. Signal. 2010, 3:re3.
46. Uversky V.N., Li J., Fink A.L. Metal-triggered structural transformations, aggregation, and fibrillation of human alpha-synuclein. A possible molecular NK between Parkinson's disease and heavy metal exposure. J. Biol. Chem. 2001, 276:44284-44296.
47. Uversky V.N., Li J., Bower K., Fink A.L. Synergistic effects of pesticides and metals on the fibrillation of alpha-synuclein: implications for Parkinson's disease. Neurotoxicology 2002, 23:527-536.
48. Wang X., Moualla D., Wright J.A., Brown D.R. Copper binding regulates intracellular alpha-synuclein localisation, aggregation and toxicity. J. Neurochem. 2010, 113:704-714.
49. Wright J.A., Wang X., Brown D.R. Unique copper-induced oligomers mediate alpha-synuclein toxicity. FASEB J. 2009, 23:2384-2393.
50. Xia Z., DePierre J.W., Nassberger L. Dysregulation of bcl-2, c-myc, and Fas expression during tricyclic antidepressant-induced apoptosis in human peripheral lymphocytes. J. Biochem. Toxicol. 1996, 11:203-204.
51. Xia Y., Saitoh T., Ueda K., Tanaka S., Chen X., Hashimoto M., Hsu L., Conrad C., Sundsmo M., Yoshimoto M., Thal L., Katzman R., Masliah E. Characterization of the human alpha-synuclein gene: genomic structure, transcription start site, promoter region and polymorphisms. J. Alzheimers Dis. 2001, 3:485-494.
52. Yang X.W., Wynder C., Doughty M.L., Heintz N. BAC-mediated gene-dosage analysis reveals a role for Zipro1 (Ru49/Zfp38) in progenitor cell proliferation in cerebellum and skin. Nat. Genet. 1999, 22:327-335.
53. Yu S., Li X., Liu G., Han J., Zhang C., Li Y., Xu S., Liu C., Gao Y., Yang H., Ueda K., Chan P. Extensive nuclear localization of alpha-synuclein in normal rat brain neurons revealed by a novel monoclonal antibody. Neuroscience 2007, 145:539-555.
54. Zarranz J.J., Alegre J., Gomez-Esteban J.C., Lezcano E., Ros R., Ampuero I., Vidal L., Hoenicka J., Rodriguez O., Atares B., Llorens V., Gomez Tortosa E., del Ser T., Munoz D.G., de Yebenes J.G. The new mutation, E46K, of alpha-synuclein causes Parkinson and Lewy body dementia. Ann. Neurol. 2004, 55:164-173.
55. Zhou W., Lo S.C., Liu J.H., Hannink M., Lubahn D.B. ERRbeta: a potent inhibitor of Nrf2 transcriptional activity. Mol. Cell. Endocrinol. 2007, 278:52-62.